Noble treatment for PTSD


Xenon may one day become a promising new treatment for post-traumatic stress disorder (PTSD) following an investigation by researchers at Harvard Medical School, US.

Edward Meloni and colleagues exposed a group of 94 rats to frightening stimuli. Rats who were administered xenon gas during a critical period of time known as the reconsolidation window – when reactivated memories become temporarily susceptible to modification – showed less fear than those who were not.

Xenon achieved this effect by inhibiting glutamatergic NMDA receptors in the brain, involved in memory reconsolidation. Exposure to xenon gas at just the right time interrupts the reconsolidation process and prevents the recollection of powerful emotions such as fear.

If similar effects are seen in humans, xenon gas could be used to help individuals suffering from PTSD.  This treatment is particularly exciting because xenon has already been shown to be safe in humans, thanks to its use as an anaesthetic and diagnostic imaging agent.


Related Content

Of mice and men

30 March 2011 Premium contentFeature

news image

2009 marked the first year that more genetically modified animals were used in UK scientific procedures than animals deemed '...

Roadblock on memory lane

25 June 2010 Feature

news image

The ability to wipe out traumatic memories is just around the corner. Katrina Megget looks into the science of forgetting

Most Read

Sun rises on new solar route to hydrogen

27 February 2015 Research

news image

Photocatalyst has solar-to-hydrogen conversion efficiency of 2% and points way to cheap production of the gas

The mothers of invention

24 February 2015 Managing Change

news image

Nina Notman profiles four researchers successfully balancing an academic career with family life

Most Commented

Sun rises on new solar route to hydrogen

27 February 2015 Research

news image

Photocatalyst has solar-to-hydrogen conversion efficiency of 2% and points way to cheap production of the gas

Hepatitis C drug patent challenged in Europe

19 February 2015 Business

news image

Campaign group says Gilead’s expensive blockbuster sofosbuvir is not innovative enough to warrant a patent